Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This company has lots of valuable, real assets. If they can't make it on their own, they can get a partner or sell it. Furthermore, they seem to be going where they planned to go, and are even ahead of schedule.
Instead of wondering, why not call the company and ask?
The last two times there was a big jump in share price (last was up to around $1.40+ from $0.75), there was a paid advertising campaign (aka a pump). I haven't received or heard of any such a campaign recently but there could be one going on. In any case, i sure hope there will be one asap! The last two made the price zoom up fast.
You said "30 rsi is close". What does that mean in regular English? is it good for us longs or not?
How about writing Kim and suggesting it? You can be quite persuasive...
I think there was a dividend last year.
What exactly was the point of Rocky's post?
I don't see what the problem is with a RS. Some people on yahoo board said they hope the company will do that. At least it would get us off the pinks and onto a regulated exchange. So less (at least) naked shorting. What are your objections to a RS?
Anything that would get the share price back up to where it was when we early investors jumped in would be a blessing, as far as i'm concerned!!!
Instead of speculating about this, how about asking Kim directly???
Instead of all this endless speculation, how about someone who understands the process pretty well--such as you or Zinc, for example--call Kim and ask him to clarify all the things that continue to be debated day after day?
Much worse than that. i can't understand it, unless naked shorts and/or manipulation. otherwise makes NO SENSE!!!!!! Bummer......
To clarify: WRT your statement "no FDA approval is required because no drugs are involved", i thought you earlier said FDA approval would be needed for medical uses.
Maybe you weren't referring to the specialty medical uses in your posting, above, since medical uses of the sort that might need FDA approval (such as infusing the sutures with antibiotics) will presumably come at a much later date. But i'd appreciate your clarification.
Thanks. Always appreciate your posts, Zinc, and feel more confident because of your confidence.
OOPs, sorry. Didn't notice question was answered. Thanx.
ZINC, plz reply: Will the FDA have to appove medical applications?
Focus on the great info. So what if he's not a great public speaker?! What matters is he's responsible for delivering great results and there are great results.
Tax losses are, i think, deducted from capital gains one-to-one. The $3000 per year allowable deduction is, i think, deducted from ordinary income. I'm not absolutely certain about either of the above statements but i believe they are both correct.
TOP-TIER MEDICAL JOURNAL "HEADACHE" PUBLISHES CLINICAL STUDY RESULTS of PuraMed BioScience, Inc. Revolutionary New Migraine Medication LipiGesic(TM) M
SCHOFIELD, Wis., Jun 2, 2011 (GlobeNewswire via COMTEX) -- PuraMed BioScience, Inc. (OTCQB:PMBS) is announcing that an independent clinical study of its non-prescription migraine medication LipiGesic(TM) M conducted by leading headache researcher Dr. Roger Cady has been published in the "Early View" section of the online edition of Headache, a top-tier medical journal of the American Headache Society, and is expected to be published in the print edition in the near future.
A video accompanying this release is available at http://globenewswire.com/mpr/puramed-bioscience/223534.html
The study found that 64 percent of subjects found pain relief within two hours of taking LipiGesic(TM) M. The study concludes that sublingual feverfew/ginger appears safe and effective as a first-line treatment for a population of migraineurs who frequently experience mild headache prior to the onset of moderate to severe headache.
"We are extremely pleased with the results of the independent study of LipiGesic(TM) M," said PuraMed BioScience CEO Russell Mitchell. "This study positions LipiGesic(TM) M as a highly effective first-line therapy for migraines. We are confident that we are introducing the best discovery in recent history for the relief of migraines."
Mitchell continued, "In addition to the higher efficacy rate, the study subjects reported minimal to no side effects. The study also indicates that LipiGesic(TM) M is safe to combine with other medications and does not require a prescription. In this time when healthcare costs continue to rise, we are pleased to offer this superior migraine treatment at a drastically more affordable rate--at least 75 percent less expensive when compared to leading prescription medications. It is also important to note that the study states that there remains a need for affordable, effective treatments for migraine sufferers, and that LipiGesic(TM) M is now recommended as a first-line treatment."
"The timing of the publishing of these study results in June perfectly aligns with National Headache Awareness Month," added Mitchell. "According to the National Headache Foundation, migraines are the most expensive brain disorder, costing the U. S. economy $31 billion in 2010, which is comprised of the cost of treatment and the cost of lost productivity and absenteeism due to this debilitating medical issue. We are pleased to provide this important breakthrough news to the medical community and to the 50 million American consumers that suffer from migraine headaches and are seeking a more effective, accessible and affordable treatment."
This multi-site, double-blind, placebo-controlled study was approved by an independent investigational review board and conducted at three headache centers in the United States. The study, titled "A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic(TM) M) in the Treatment of Migraine," was conducted by lead investigator Roger K. Cady, MD with the assistance of two additional nationally recognized investigators, Jerome Goldstein, MD, of San Francisco, Calif. and Robert Nett, MD, RPh, of San Antonio, Texas.
Dr. Roger Cady is the founder of Headache Care Center, Clinvest, and Primary Care Education Network. He is a graduate of the Mayo Medical School, and is Board Certified by the American Board of Family Practice. His board certification in Headache Medicine was awarded by the United Council for Neurologic Subspecialties, and he holds a Certificate of Added Qualification through the National Board of Certification in Headache Management. He is a member of multiple medical associations, including the American Medical Association, the National Headache Foundation, the American Headache Society, the American Academy of Pain Management, and the American Academy of Family Physicians. Dr. Cady is best known in the medical community for his pivotal contributions in the field of headache and migraine management. He was the co-recipient of the prestigious Wolff Award in 2000 from the American Headache Society for his research entitled "The Spectrum of Headache". He is well-published and has presented countless lectures and seminars around the world on headache, migraine, and other chronic disorders, and continues to be the principal investigator in numerous multi-center research studies. Dr. Cady currently serves on 12 Advisory Boards and is a member of the Board of Directors for the National Headache Foundation.
To view the abstract for this study, visit the Headache homepage and click on the "Early View" section:http://www.headachejournal.org/view/0/index.html
For more information on LipiGesic(TM) M and to purchase, visit www.LipiGesicM.com.
HERE IS ARTICLE AND VIDEO WE HAVE BEEN WAITING FOR!
http://finance.yahoo.com/news/Video-Rele...
i don't remember exactly but i think it was 1.25 or close to that.
GREAT INFO about JAMN from "How to Hack the Stock Market" in this alert they sent out today titled "Another Bite at the JAMN Apple"
In the past few weeks my JAMN pick
has given us quite a ride.
From humble beginnings of under $1
JAMN has rocketed.
At its peak JAMN reached $6.35!
But in the past few days JAMN has
dropped considerably.
As of writing it's trading at $1.07
This unprecedented fall has given
us yet another bite of the cherry.
I believe this sharp fall is unwarranted
and has provided a low downside
opportunity in JAMN.
JAMN has fallen for two reasons.
#1 JAMN has been attacked by short
sellers.
Short sellers including the sponsoring
market maker and related parties
have attempted to crush JAMN.
They've done this by selling millions
and millions of JAMN shares'.
By ensuring supply outstripped demand
they have manipulated the price of
JAMN downwards.
But, this price manipulation is only
temporary.
By law these short sellers MUST buy
back every single share' they've sold
short.
And they must complete this buying
within 5 days.
Which means JAMN is I believe almost
guaranteed to bounce on the wave
of buying from short sellers looking
to cover their positions.
#2 Jammin released their 10-K annual
report.
This report showed minimal sales for
the quarter ending January 31st.
I believe this release fuelled the
negative rumors spread by short
sellers.
But this reaction is entirely without
merit.
Jammin Java only started their
nationwide rollout in February.
In the quarter ending Jan 31st JAMN
was still a development stage company.
i.e. They weren't even trying to
generate sales.
All the deals they've signed have
been since February:
JAMN Contract with United Natural Foods
- February 23rd
JAMN contract with Gourmet Merchants Intl.
- March 16th
JAMN contract with Amazon.com
- March 31st
JAMN contract with National Coffee Service
- April 12th
JAMN launches Coffee Pods Product Line
- April 14th
JAMN sells out within 1 Hour at Amazon Launch
- April 20th
JAMN receives $2.5m financing
- May 6th
So large sales won't be reported to
Wall Street until the next quarter.
Why I believe you should look
at JAMN again...
On a short-term basis I see JAMN
as a huge opporunity right now.
When a stock drops this much, this
fast...
For one thing, there is always a
bounce.
And for another thing...
As the short sellers who've pushed
JAMN to these levels start covering
it will add rocket fuel to the bounce.
As a natural bounce occurs along
with millions of shares' being
bought by short sellers - We could
even see another short squeeze.
John Bell
P.S. The last time I sent you a similar
email was when JAMN was at $1.40.
Just like today I predicted the
short squeeze could send JAMN rocketing.
It reached $6.35 in the weeks following.
JAMN is now under $1.40 and I'm making
the exact same call.
Don't miss out again.
Start researching JAMN for yourself
today.
EERG vs AMZG: CORRECTION TO MY PREVIOUS POST
EERG is not down since the merger announcement but it is down significantly relative to the highs it reached since the announcement, whereas AMZG has gone straight up since the announcement.
EERG is surviving company. After the merge, reverse split to reduce total number of shares, with EERG shareholders getting 20% and AMZG shareholders getting 80%. So EERG actually does better than AMZG, it seems to me, doing the numbers. Yet AMZG has gone up from $1.88 to $2.12 since the announcement while EERG has gone down. I don't get it...i'd sure like to know why. (I sold my AMZG to buy EERG)